Background	B-O
Influenza	B-O
is	B-O
a	B-O
cause	B-O
of	B-O
febrile	B-O
acute	B-O
respiratory	B-O
infection	B-O
.	B-O
Observation	B-O
period	B-O
for	B-O
each	B-O
child	B-O
began	B-O
14	B-O
days	B-O
postreceipt	B-O
of	B-O
final	B-O
vaccine	I-LF
dose	B-O
each	B-O
year.	B-O
Children	B-O
with	B-O
at	B-O
least	B-O
4	B-O
weeks	B-O
of	B-O
follow-up	B-O
during	B-O
the	B-O
observation	B-O
period	B-O
for	B-O
a	B-O
given	B-O
study	B-O
year	B-O
were	B-O
included	B-O
in	B-O
the	B-O
analysis	B-O
until	B-O
the	B-O
earliest	B-O
of	B-O
the	B-O
following	B-O
censoring	B-O
events:	B-O
influenza	I-LF
virus	B-O
infection	B-O
.	B-O
During	B-O
Year	B-O
1,	B-O
42	B-O
children	B-O
emigrated	B-O
and	B-O
3	B-O
died.	B-O
For	B-O
Year	B-O
2,	B-O
of	B-O
2,996	B-O
.	B-O
Baseline	B-O
characteristics	B-O
including	B-O
age,	B-O
nutritional	B-O
status,	B-O
and	B-O
household	B-O
characteristics	B-O
were	B-O
similar	B-O
between	B-O
the	B-O
4	B-O
groups	B-O
.	B-O
During	B-O
Year	B-O
2,	B-O
total	B-O
influenza	I-LF
virus	B-O
circulation	B-O
was	B-O
higher	B-O
than	B-O
in	B-O
Year	B-O
1,	B-O
with	B-O
longer	B-O
peak	B-O
periods,	B-O
from	B-O
June	B-O
2016	B-O
through	B-O
September	B-O
2016	B-O
;	B-O
Round	B-O
2:	B-O
July	B-O
14	B-O
to	B-O
August	B-O
7	B-O
.	B-O
Sequencing	B-O
of	B-O
the	B-O
haemagglutinin	[{'token': 'haemagglutinin', 'label': 'B-LF'}]
,	B-O
we	B-O
observed	B-O
that	B-O
in	B-O
the	B-O
first	B-O
6	B-O
months	B-O
postvaccination	B-O
in	B-O
both	B-O
years,	B-O
relative	B-O
efficacy	B-O
of	B-O
LAIV	B-AC
compared	B-O
with	B-O
IIV	B-AC
was	B-O
not	B-O
significantly	B-O
different	B-O
.	B-O
Local	B-O
adverse	B-O
events	B-O
were	B-O
more	B-O
common	B-O
in	B-O
the	B-O
injection	B-O
group/s	B-O
as	B-O
compared	B-O
with	B-O
the	B-O
nasally	B-O
administered	B-O
groups.	B-O
Recurrent	B-O
wheezing	B-O
was	B-O
reported	B-O
by	B-O
approximately	B-O
1%	B-O
of	B-O
children	B-O
over	B-O
the	B-O
2-year	B-O
period	B-O
and	B-O
not	B-O
significantly	B-O
different	B-O
between	B-O
groups.	B-O
SAEs	B-O
were	B-O
rare,	B-O
and	B-O
none	B-O
were	B-O
attributed	B-O
to	B-O
be	B-O
causally	B-O
related	B-O
to	B-O
vaccination.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Table	B-O
4.	B-O
Adverse	B-O
events	B-O
associated	B-O
with	B-O
live	B-LF
attenuated	I-LF
and	B-O
inactivated	B-LF
influenza	I-LF
vaccines	B-O
within	B-O
42	B-O
days	B-O
post-administration,	B-O
aggregated	B-O
across	B-O
study	B-O
years.	B-O
Discussion	B-O
This	B-O
2-year,	B-O
triple-blind,	B-O
large	B-O
community-based	B-O
trial	B-O
demonstrated	B-O
that	B-O
both	B-O
indigenously	B-O
produced	B-O
Russian-backbone	B-O
LAIV	B-AC
and	B-O
commercially	B-O
available	B-O
IIV	B-AC
were	B-O
safe	B-O
and	B-O
moderately	B-O
efficacious	B-O
against	B-O
laboratory-confirmed	B-O
influenza-associated	B-O
FARI	B-AC
among	B-O
children	B-O
aged	B-O
2	B-O
to	B-O
10	B-O
years	B-O
in	B-O
rural	B-O
India.	B-O
In	B-O
Year	B-O
1,	B-O
single-dose	B-O
LAIV	B-AC
provided	B-O
some	B-O
protection	B-O
to	B-O
a	B-O
vaccine-na√Øve	B-O
population	B-O
but	B-O
significantly	B-O
less	B-O
than	B-O
IIV,	B-O
whereas	B-O
in	B-O
Year	B-O
2,	B-O
LAIV	B-AC
and	B-O
IIV	B-AC
efficacies	B-O
were	B-O
similar.	B-O
Importantly,	B-O
during	B-O
both	B-O
years,	B-O
both	B-O
vaccines	B-O
were	B-O
protective	B-O
against	B-O
influenza	I-LF
A	B-O
S2	B-O
Fig.	B-O
Analysis	B-O
flowchart:	B-O
description	B-O
of	B-O
data	B-O
flow	B-O
for	B-O
mITT	B-AC
analysis	B-O
of	B-O
LAIV	B-AC
trial.	B-O
LAIV,	B-O
live	B-LF
attenuated	I-LF
influenza	I-LF
vaccine;	B-O
mITT,	B-O
modified	B-LF
intention-to-treat.	B-O
